Lenvatinib Plus Tislelizumab With or Without TACE in First-line Treatment of Unresectable HCC

NCT05842317 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Hepatocellular Carcinoma

Interventions

DRUG: Lenvatinib Plus Tislelizumab
DEVICE: Transarterial Chemoembolization(TACE)

Sponsor

Peking Union Medical College Hospital